This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.
Lyme disease from exposure to follow-up
A high-risk bite raises the question of prophylaxis. Established infection raises different questions about disease stage, test interpretation, and treatment by site. Symptoms after treatment call for reassessment for reinfection, an untreated manifestation, or another cause.
Companion lecture: Acute tick-borne infections. Use it for prominent febrile cytopenias, hemolysis, eschars, tularemia, or failure to improve on doxycycline.
Where Lyme exposure is most likely
Lyme disease is most common in the Northeast, mid-Atlantic and upper Midwest, with smaller areas of transmission along the Pacific Coast. The location of outdoor exposure and travel is more informative than residence alone.
Sources CDC Lyme overview; CDC transmission geography.
Interactive map and other U.S. tick-borne infections | International exposures
CDC reference and jurisdiction grouping. Geographic review October 31, 2026.
Travel to Canada, Europe, or temperate Asia changes the exposure assessment. Canada; Europe and temperate Asia.
Bite-site lesions and systemic rashes
Lyme is caused primarily by B. burgdorferi in the U.S.; B. mayonii is uncommon. Relevant exposure is concentrated in the Northeast, mid-Atlantic, upper Midwest, and focal Pacific Coast areas. Exposure location is more informative than residence alone.
U.S. regional map and international exposure map. Northeast/mid-Atlantic, upper Midwest and focal Pacific Coast exposures have different background risks; location alone cannot diagnose or exclude Lyme.
A photograph cannot identify the pathogen. Erythema migrans expands over days and need not have central clearing. An immediate small itchy reaction that fades over 1-2 days favors local bite hypersensitivity. Size alone is not definitive: early erythema migrans may initially be small. The diameter and change over time can help distinguish the two.
For additional erythema migrans appearances across skin tones and bite-reaction mimics, use the CDC clinical photograph gallery. Individual third-party photographs there are linked rather than reproduced.
STARI can resemble erythema migrans after a lone star tick bite. There is no validated diagnostic test and antibiotic benefit is uncertain. In regions endemic for both, uncertainty between STARI and erythema migrans favors Lyme-directed treatment. A necrotic eschar or prominent regional nodes should prompt the eschar/tularemia differential.
Test according to the stage
Standard two-tier testing uses an enzyme immunoassay (EIA), followed by an immunoblot if the first assay is positive or equivocal. Modified two-tier testing uses two different EIAs in an FDA-cleared sequence. The completed algorithm determines the result. Individual bands and a reactive screening result alone are insufficient. A negative first tier generally stops testing on that specimen. A later sample can clarify an early negative result when suspicion remains. Early antibiotic treatment can prevent seroconversion.
| Situation | Clinical interpretation |
|---|---|
| Typical erythema migrans with compatible exposure | A typical lesion with compatible exposure supports a clinical diagnosis. Early serology often remains negative and is unnecessary in this setting. |
| Atypical lesion or suspected extracutaneous disease | FDA-cleared standard or modified two-tier testing helps assess these presentations. When the first sample is negative in suspected atypical erythema migrans, a convalescent sample at least 2-3 weeks later can help. |
| Symptoms lasting more than 30 days | Isolated IgM does not support Lyme disease after 30 days of illness. A negative validated IgG after months to years of untreated symptoms strongly argues against Lyme, with rare exceptions such as humoral immune deficiency. |
| Positive antibody after previous treatment | Antibodies can persist for years. The result cannot distinguish past infection from active disease and has no role as a test of cure. |
| Potential cross-reaction | Relapsing-fever Borrelia, syphilis, EBV, and rheumatoid arthritis can produce misleading results. Exposure and clinical findings determine how much weight to give the completed test. |
EBV, Epstein-Barr virus; FDA, Food and Drug Administration; IgG/IgM, immunoglobulin G/M. CNS, central nervous system; CSF, cerebrospinal fluid; EIA, enzyme immunoassay; PCR, polymerase chain reaction.
Sensitivity, specificity, CSF testing, and synovial-fluid PCR. Suspected relapsing fever requires pathogen-specific testing.
Lumbar puncture and CSF interpretation
LP can help assess suspected meningitis, encephalitis, myelitis, or raised intracranial pressure. Its value in isolated facial palsy or peripheral radiculoneuropathy depends on the differential and evidence of CNS involvement. Fatigue or cognitive complaints alone do not justify CSF Lyme testing.
Serum two-tier testing is the first Lyme test in suspected neuroborreliosis. When CSF evaluation is indicated, routine CSF studies and a validated antibody index from paired CSF and serum address different diagnostic questions. Active CNS disease usually causes lymphocytic pleocytosis. An elevated index may persist after cure; a normal index does not exclude early disease.
The AAN/ACR/IDSA guideline cites 17% CSF PCR sensitivity in a meta-analysis of acute neuroborreliosis. In a US pediatric meningitis study, PCR was positive in only 1 of 20 children meeting the study definition of Lyme meningitis (5%). These are study- and assay-specific estimates, not universal adult test characteristics. Routine CSF PCR is not recommended; a negative result cannot exclude infection.
LP also helps identify alternative infections. See the acute CNS evaluation and neurologic treatment regimens.
Treatment of erythema migrans
| Oral option for adult erythema migrans | Duration |
|---|---|
| Doxycycline | 10 days per the AAN/ACR/IDSA guideline. CDC lists 10-14 days and favors the shorter effective course. |
| Amoxicillin | 14 days |
| Cefuroxime axetil | 14 days |
Severe renal impairment and dialysis affect amoxicillin and cefuroxime exposure. Product labeling describes the adjustments for each drug. Amoxicillin label; cefuroxime label.
Allergy, pregnancy, tolerability, and possible coinfection can change the choice. Amoxicillin and cefuroxime are usual options for uncomplicated erythema migrans in pregnancy. Doxycycline in pregnancy calls for an individualized risk-benefit discussion. Amoxicillin and cefuroxime lack activity against anaplasmosis and ehrlichiosis. Azithromycin is a second-line option when doxycycline and the beta-lactams cannot be used. Multiple lesions can still be treated orally when there is no neurologic or cardiac indication for IV therapy.
Neurologic, cardiac, and joint manifestations
Syncope, palpitations, dyspnea, chest pain, or lightheadedness raise concern for carditis and warrant an ECG. Routine ECG screening is not recommended when there are no cardiac symptoms or signs. Nonspecific ECG changes alone do not establish Lyme carditis.
Untreated infection can disseminate to skin, nerves, heart, or joints. Delayed treatment can leave neurologic injury or joint damage; conduction disease can become life-threatening. Persistent injury after eradication does not by itself establish persistent infection.
| Manifestation / decision | Treatment and follow-up |
|---|---|
| Isolated Lyme facial palsy | CDC lists oral doxycycline for 14-21 days. Impaired eye closure calls for corneal protection. CDC neurologic Lyme guidance. Evidence is insufficient to support or oppose adjunctive corticosteroids for confirmed Lyme facial palsy. In patients aged 16 years or older with acute facial palsy and no other objective clinical or serologic evidence of Lyme disease, the usual 72-hour corticosteroid window for idiopathic facial palsy still applies while Lyme testing is pending. AAN/ACR/IDSA recommendation XV [7]. |
| Lyme meningitis or radiculoneuritis without brain or spinal cord parenchymal disease | Oral doxycycline or IV ceftriaxone are options for 14-21 days. Severity, oral tolerance, and competing causes of meningitis inform the route. CDC neurologic Lyme guidance. |
| Encephalitis or myelitis attributable to Lyme | Parenchymal Lyme disease favors IV therapy, commonly ceftriaxone. Courses of 2-4 weeks have been used, but there are no comparative duration studies. Objective brain or spinal cord inflammation is distinct from nonspecific cognitive symptoms. |
| Stable mild carditis, first-degree block with PR <300 ms | Oral doxycycline, amoxicillin, or cefuroxime axetil for 14-21 days are options for clinically mild disease with close follow-up. |
| Severe or high-risk carditis | Syncope or presyncope, a PR interval of at least 300 ms, second- or third-degree AV block, other significant arrhythmia, or myopericarditis can signal risk of rapid deterioration. Suspected severe carditis requires hospital admission with continuous ECG monitoring and treatment before serologic confirmation. IV ceftriaxone is the usual initial Lyme-directed agent. After symptoms and any high-grade AV block resolve, oral therapy can complete 14-21 days total. Temporary pacing may be needed. |
| Initial Lyme arthritis | Objective swelling usually affects one or a few large joints, often the knee. Oral doxycycline, amoxicillin, or cefuroxime axetil for 28 days are initial treatment options. If bacterial septic arthritis remains plausible, prompt joint aspiration for bacterial culture is needed even with positive Lyme serology. Synovial fluid crystal analysis can assess the competing crystal diagnosis. |
| Mild residual swelling after first arthritis course | Resolution can lag behind treatment. Adherence, alternate diagnoses, and the degree and trend of swelling help interpret the response. Comparative evidence is insufficient to choose between observation and a second oral course. |
| Minimal/no improvement with persistent substantial swelling after first oral course | After reassessment, IV ceftriaxone for 14-28 days is the suggested next course when substantial swelling has improved minimally or not at all. |
| Persistent synovitis after adequate oral and IV courses | Persistent synovitis can reflect post-antibiotic Lyme arthritis. Rheumatology can assess anti-inflammatory or DMARD options. Serial antibiotic courses after adequate oral and IV treatment lack established benefit. |
CSF pleocytosis alone does not determine the route of therapy. For established Lyme meningitis without parenchymal disease, oral doxycycline is an accepted option. Initial IV treatment may be needed for severe illness, unreliable oral intake, or empiric coverage of other CNS infections. Amoxicillin and oral cefuroxime are not established treatment options for neurologic Lyme disease. Combined hepatic dysfunction and significant renal disease carry a labeled ceftriaxone ceiling of 2 g/day. ceftriaxone label. CNS treatment for other tick-borne infections.
AV, atrioventricular. DMARD, disease-modifying antirheumatic drug. ECG, electrocardiogram. IV, intravenous. PR, atrioventricular conduction interval on ECG.
Fever or cytopenias that do not fit uncomplicated Lyme
Prominent leukopenia, thrombocytopenia, or hemolytic anemia should prompt consideration of another tick-borne infection. Persistent fever on doxycycline raises the possibility of babesiosis or another diagnosis.
Doxycycline treats anaplasmosis. Babesiosis requires different therapy. With hemolysis, a manual blood smear or Babesia PCR helps assess coinfection. Use the companion lecture for initial specimens, Babesia regimens, and persistent-fever reassessment.
For persistent febrile cytopenias or encephalitis, see Heartland, Bourbon, Powassan and Colorado tick fever testing. Memory aids, including Babesia treatment.
Babesia geography differs by species. Missouri-acquired divergens-like/MO-1 infection is documented, and a B. microti-only assay can miss non-microti disease. See the species-specific map and Missouri exception.
Persistent symptoms and the label "chronic Lyme disease"
The label does not specify whether the patient has untreated infection, reinfection, post-infectious symptoms, residual organ injury, or another diagnosis. Fatigue, diffuse pain, poor sleep, and cognitive difficulty can be disabling after treated Lyme disease; their mechanism is not established, and their presence does not prove viable Borrelia persists.
| Clinical situation | Clinical interpretation |
|---|---|
| Documented untreated Lyme manifestation | A first course directed at the documented manifestation remains appropriate even after a long symptom duration. |
| New erythema migrans after a new exposure | A new typical lesion after new exposure can represent reinfection and warrants treatment. Serology may still reflect the earlier episode. |
| Objective recurrent arthritis, meningitis, neuropathy, or cardiac findings | The previous diagnosis, regimen and adherence help distinguish reinfection, treatment failure, and alternative causes. A documented active manifestation can justify additional antibiotics. Antibody positivity alone cannot. |
| Persistent fatigue, pain, or cognitive symptoms after appropriate treatment without objective evidence of active infection | Additional antibiotics have no established role in this setting. Sleep disorders, anemia, endocrine disease, medication effects, mood symptoms, neurologic disease, and other infections may explain symptoms. Care can address symptoms and follow function over time. |
| Positive Lyme antibody but no compatible syndrome | No antibiotics solely for the test result. Prior exposure, false positivity, and cross-reactivity are possible. |
| Nonspecific chronic symptoms with repeatedly negative appropriate late serology and no credible exposure | Lyme is unlikely. An empiric prolonged-antibiotic course cannot establish the diagnosis. |
Post-treatment Lyme disease syndrome (PTLDS) is commonly defined for research by documented Lyme disease, recommended treatment with resolution or stabilization of objective findings, and functionally important fatigue, widespread pain, or cognitive complaints beginning within six months of diagnosis and persisting for at least six months after completing treatment, without a better explanation. These criteria do not prove a mechanism and are not a reason to defer symptom care until six months.
After a bite and after treatment
The AAN/ACR/IDSA definition of a high-risk bite requires an identified Ixodes vector, a highly endemic exposure area, and at least 36 hours of attachment. For a qualifying bite in an adult or child, single-dose oral doxycycline within 72 hours of removal reduces Lyme risk. Doxycycline allergy affects suitability. In pregnancy, the decision depends on an individualized, informed discussion of the risks and benefits. If the bite does not clearly meet the criteria or doxycycline cannot be used, observation with symptom counseling is appropriate. No alternative single-dose regimen is established. Erythema migrans requires a treatment course. Routine prophylaxis for RMSF, ehrlichiosis, and anaplasmosis is not recommended.
Prompt removal with fine-tipped tweezers near the skin limits attachment time. EPA-registered repellent, permethrin-treated clothing, and skin checks help prevent bites or prolonged attachment. Fever, expanding rash, eschar, dyspnea, syncope, or neurologic symptoms after a bite warrant assessment. Lyme serology in an asymptomatic person and pathogen testing of the tick do not guide treatment.
Follow-up centers on clinical recovery and new objective findings. Reinfection remains possible. Syncope, palpitations, dyspnea, facial weakness, severe radicular pain, or joint swelling warrant reassessment.
Cases for discussion
Treated Lyme, fatigue and poor concentration nine months later, no synovitis or neurologic deficit, persistent IgG.
Persistent IgG does not establish treatment failure. This presentation warrants assessment for other causes and symptom-focused care. The available findings do not support additional antibiotics.
New swollen knee months after untreated Lyme-compatible illness, strong IgG response. Same decision?
Objective swelling changes the differential. Lyme arthritis is plausible with this history and IgG result, and a confirmed diagnosis warrants a defined course. Positive Lyme IgG does not rule out bacterial septic arthritis. If bacterial infection remains plausible, the acute evaluation includes prompt arthrocentesis and synovial bacterial culture.
Diagnostic performance and difficult interpretations
| Test / question | Evidence and interpretation |
|---|---|
| Lyme two-tier sensitivity and specificity | Historical standard two-tier studies summarized by Moore et al. report approximately 30-40% sensitivity early, 70-100% with disseminated disease, and >95% specificity. These are stage- and assay-dependent estimates, not a single performance number for every modern modified two-tier assay. |
| Late Lyme arthritis | Serum IgG is generally strongly positive; guideline-reviewed conventional two-tier sensitivity is about 95-100%. IgM alone or limited IgG reactivity should prompt reconsideration. |
| Suspected CNS Lyme | Serum antibody testing is the first Lyme test. When CSF testing is indicated, a validated index requires simultaneous CSF and serum. Intrathecal antibodies can persist after cure, so CSF inflammation and clinical findings inform interpretation. Routine blood/CSF PCR has poor sensitivity. |
| Synovial-fluid PCR | Can support Lyme arthritis in a seropositive patient when uncertainty affects management. Positive DNA after therapy does not prove viable bacteria or justify indefinite retreatment. |
Trials of prolonged antibiotics
| Trial / population | Intervention and result | Interpretation |
|---|---|---|
| Klempner et al., NEJM 2001 Two trials, 129 previously treated patients, seropositive and seronegative groups | 30 days IV ceftriaxone then 60 days oral doxycycline versus matching placebo. No advantage in the primary health-related quality-of-life outcome | Applies to persistent symptoms after documented treated Lyme, not untreated arthritis or meningitis. |
| Krupp et al., STOP-LD, Neurology 2003 55 patients with persistent severe fatigue | 28 days IV ceftriaxone versus placebo. A fatigue outcome improved; cognition did not. Four treatment-associated events required hospitalization, three in placebo recipients | The fatigue result did not establish a consistent benefit across outcomes. The investigators weighed it against the adverse events and did not recommend retreatment. |
| Fallon et al., Neurology 2008 37 patients with objective memory impairment and prior IV treatment | 10 weeks IV ceftriaxone versus placebo. Cognitive improvement at week 12 was not sustained at week 24. Some secondary pain/function signals favored treatment; drug/line events occurred in 6/23 treated versus 1/14 placebo patients | Small selected population; short-term or secondary signals do not establish a durable overall benefit or persistent infection. |
| Berende et al., PLEASE, NEJM 2016 281 randomized patients (280 in the modified intention-to-treat analysis) with persistent symptoms attributed to Lyme | All received two weeks ceftriaxone, then 12 weeks doxycycline, clarithromycin/hydroxychloroquine, or placebo. Longer oral therapy did not improve health-related quality of life; four serious drug-related events occurred during the common two-week ceftriaxone phase | Tests the value of additional oral treatment after ceftriaxone; it cannot prove initial ceftriaxone was necessary or beneficial. |
Across these trials, prolonged therapy has not shown a consistent durable benefit sufficient to outweigh harms. Potential harms of prolonged treatment include IV line infection/thrombosis, drug reactions, biliary complications, and antibiotic-associated colitis; these were not all measured uniformly in every trial. The cause of persistent symptoms remains uncertain. These trials support symptom-focused care and do not establish a routine role for prolonged, rotating, or combination antibiotics.
Sources and related lectures
Image credits appear with each figure.
- CDC Tickborne Diseases of the United States, reference manual
- IDSA babesiosis guideline, 2020
- CDC anaplasmosis clinical care
- CDC Lyme rash gallery
- CDC PHIL image 9875, James Gathany
- CDC Lyme testing
- AAN/ACR/IDSA Lyme guideline, 2020
- CDC erythema migrans treatment, March 2026
- CDC babesiosis clinical care
- CDC neurologic Lyme treatment
- CDC Lyme carditis treatment, reviewed September 2026
- CDC Lyme arthritis treatment
- CDC chronic symptoms and Lyme, June 2026
- CDC prolonged-symptom clinical resources
- Moore et al. Lyme laboratory testing, EID 2016
- Klempner et al., NEJM 2001
- Krupp et al., STOP-LD, Neurology 2003
- Fallon et al., Neurology 2008
- Berende et al., PLEASE, NEJM 2016
- Avery et al. CSF PCR in children with Lyme meningitis, 2005
Related modules: Antibiotic selection and toxicity; lecture catalog.